A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety,
tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in
adult patients with advanced solid.